Compass Pathways Rallies Pre-Market on FDA Trade Speculation
Compass Pathways shares jumped 19.5% to $12.39 in U.S. premarket trading Monday after the company announced a faster FDA review path for its COMP360 psilocybin treatment. Management will address investors Tuesday at the RBC Capital Markets conference. Compass ended March with $466 million in cash and reported a first-quarter operating loss of $42.9 million.